Study S003240

A Phase 1, Double-Blind, Randomized, Ascending-Dose, Placebo-Controlled, Multiple-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets Orally Administered in Non-diabetic Overweight or Obese Adult Subjects

ClinicalTrials.gov record

Registration

Registration: NCT07166081
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: RECRUITING
Enrollment: 80
Start: 2025-08-11
Primary completion: 2026-01-12
Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Conditions: Non-diabetic Overweight or Obese
Interventions: DRUG:BGM0504; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Number of treatment adverse events [11 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.